Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.

Cohan D, Feakins C, Wara D, Petru A, McNicholl I, Schillinger D, Lu J, Kuritzkes D, Deeks SG.

AIDS. 2005 Jun 10;19(9):989-90. No abstract available.

PMID:
15905684
2.

Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?

Morse C, Maldarelli F.

J Infect Dis. 2007 Feb 1;195(3):318-21. Epub 2006 Dec 21. Review. No abstract available.

PMID:
17205468
3.

Resistance to enfuvirtide, the first HIV fusion inhibitor.

Greenberg ML, Cammack N.

J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1. Review.

PMID:
15231762
4.

Enfuvirtide, the first fusion inhibitor to treat HIV infection.

Poveda E, Briz V, Soriano V.

AIDS Rev. 2005 Jul-Sep;7(3):139-47. Review.

PMID:
16302461
5.

Reassessment of enfuvirtide's role in the management of HIV-1 infection.

Marr P, Walmsley S.

Expert Opin Pharmacother. 2008 Sep;9(13):2349-62. doi: 10.1517/14656566.9.13.2349 . Review.

PMID:
18710359
6.

[Enfuvirtide: first drug of a new family of antiretroviral agents].

Espona M, Ferrández O, Grau S, Carmona A.

Farm Hosp. 2005 Nov-Dec;29(6):375-83. Review. Spanish.

7.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D.

Nat Rev Drug Discov. 2004 Mar;3(3):215-25. Review.

PMID:
15031735
8.

Enfuvirtide: first fusion inhibitor for treatment of HIV infection.

Jamjian MC, McNicholl IR.

Am J Health Syst Pharm. 2004 Jun 15;61(12):1242-7. Review.

PMID:
15259753
9.

Entry inhibitors in the treatment of HIV-1 infection.

Tilton JC, Doms RW.

Antiviral Res. 2010 Jan;85(1):91-100. doi: 10.1016/j.antiviral.2009.07.022. Epub 2009 Aug 14. Review.

PMID:
19683546
10.

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.

Fung HB, Guo Y.

Clin Ther. 2004 Mar;26(3):352-78. Review.

PMID:
15110129
11.

HIV entry inhibitors: progress in development and application.

Lai WH, Huang L, Chen CH.

Yao Xue Xue Bao. 2010 Feb;45(2):131-40. Review.

PMID:
21348414
12.

HIV-1 drug-resistance and drug-dependence.

Baldwin C, Berkhout B.

Retrovirology. 2007 Oct 25;4:78. Review.

13.

Enfuvirtide: a review of its use in the management of HIV infection.

Oldfield V, Keating GM, Plosker G.

Drugs. 2005;65(8):1139-60. Review. Erratum in: Drugs. 2005;65(12):1667.

PMID:
15907147
14.

Enfuvirtide (Fuzeon): the first fusion inhibitor.

Williams IG.

Int J Clin Pract. 2003 Dec;57(10):890-7. Review.

PMID:
14712892
15.

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.

Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh J, Soriano V, Schapiro J.

AIDS. 2004 May 21;18(8):1137-46. Review.

PMID:
15166529
16.

Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.

Cervia JS, Smith MA.

Clin Infect Dis. 2003 Oct 15;37(8):1102-6. Epub 2003 Sep 10. Review.

PMID:
14523775
17.

HIV entry inhibitors.

Esté JA, Telenti A.

Lancet. 2007 Jul 7;370(9581):81-8. Review.

PMID:
17617275
18.

HIV fusion inhibitors.

Pozniak A.

J HIV Ther. 2001 Nov;6(4):91-4. Review. No abstract available.

PMID:
11740409
19.

T-20: a model for novel anti-HIV drugs in development.

Laurence J.

AIDS Read. 2002 Nov;12(11):469-70. Review. No abstract available.

PMID:
12494906
20.

Case histories, magic bullets and the state of drug discovery.

Drews J.

Nat Rev Drug Discov. 2006 Aug;5(8):635-40. Epub 2006 Apr 13. Review.

PMID:
16883301

Supplemental Content

Support Center